Stockreport

Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation [Yahoo! Finance]

COCHLEAR PLC UNSP/ADR  (CHEOY) 
PDF Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent [Read more]